

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)


PCT

(10) International Publication Number  
**WO 03/073996 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K** (US). **LI, Xiankui** [CN/US]; 1514 S. Fourth Street #B, Alhambra, CA 91803 (US).
- (21) International Application Number: PCT/US03/06314
- (22) International Filing Date: 3 March 2003 (03.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/361,528 1 March 2002 (01.03.2002) US
- (71) Applicant (for all designated States except US): **HOUSE EAR INSTITUTE** [US/US]; 2100 W. Third Street, Los Angeles, CA 90057 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HUNG, Gene** [US/US]; 8563 Galway Place, San Diego, CA 92129
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: HUMAN SCHWANNOMA CELL LINE



(57) Abstract: In a preferred embodiment, the present invention relates to a Schwannoma cell line derived from a Schwann tumor in a patient with Neurofibromatosis type 2 (NF2) and immortalized with HPV E6-E7 genes. The cell line has a unique splice site mutation of the NF2 gene. The immortalized cell line is non-tumorigenic but has altered growth properties such as higher proliferation rate and independence of Schwann cell growth factors. Methods of using this unique cell line for pharmacologic screening are disclosed.